Dr. David W Malka, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 7539 Medical Drive, Hudson, FL 34667 Phone: 727-869-2115 Fax: 727-863-6167 |
Indira Umamaheswaran, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 7539 Medical Dr, Hudson, FL 34667 Phone: 727-869-2115 Fax: 727-863-6167 |
Dr. Qin Gu, Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 7539 Medical Drive, Hudson, FL 34667 Phone: 727-869-2115 Fax: 727-863-6167 |
Mrs. Riqueza Yambao Galura Cua, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 13939 Lakeshore Blvd, Hudson, FL 34667 Phone: 727-863-0063 Fax: 727-962-7163 |
News Archive
Results of a long QT syndrome (LQTS) study published in the current issue of Circulation play an important role in understanding genetic testing's role in diagnosing disease, according to the senior author, Michael Ackerman, M.D., Ph.D. A pediatric cardiologist at Mayo Clinic, Dr. Ackerman directs Mayo's Long QT Syndrome Clinic and is the director of the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory.
ChromaDex Corp., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM, the global life sciences and material sciences company.
Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.
Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.
› Verified 2 days ago